Loading...

ANAB ANAPTYSBIO INC Contract Awards 8-K Filing

NPTY

NB

ANAPTYSBIO INC

(ANAB)

2024 8-K

Show Summary

Show Summary

Product Expansion

Financial Statements

Stock Repurchase

Financial Results

Investor Presentation

Clinical Trial Results

License Agreement

Financial Results

Financial Results Announcement

Annual Meeting of Stockholders

Earnings Reports

Financial Results Announcement

Financial Information Prese...

License Agreement with Cent...

Earnings Report

Clinical Trial Results

Management Changes

Financial Results Announcement

Annual Meeting of Stockholders

Earnings Report

Resignation and Appointment...

Financial Results Announcement

Amendment to Bylaws

Stock Repurchase Plan

Financial Update

External Links:

AnaptysBio, Inc. announced that its Phase 2B Trial of ANB032 for atopic dermatitis did not meet its primary and secondary goals, but the drug was well tolerated; the company also expects to have approximately $415 million in cash reserves by year-end

AI Assistant

ANAPTYSBIO INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.